Affiliation:
1. Department of Dental Oncology and Maxillofacial Prosthetics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
2. Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada
3. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Abstract
PURPOSE: Patients with newly diagnosed acute myeloid leukemia (AML) are at risk of infection, including odontogenic infections, during induction chemotherapy. It is unknown whether clinical dental screening to diagnose and treat odontogenic disease in these patients can reduce the incidence of dental emergencies. METHODS: Between November 1, 2014, and December 31, 2016, we screened 147 patients with newly diagnosed AML before their admission for induction chemotherapy (n1 = 147, “screened” group). The patients not screened acted as controls (n2 = 190, “unscreened” group), as did patients diagnosed with AML in the 26 months before the initiation of the screening program (n3 = 304, “prescreening” group). The number of patients in each group who presented for emergency dental assessment during admission for induction chemotherapy was determined by 2 independent reviewers. RESULTS: Among the 147 patients in the screened group, only 1 patient presented with an infectious odontogenic emergency (0.68% [95% CI, −0.64% to 1.98%]). In the unscreened group, 8 developed an infectious odontogenic emergency during induction chemotherapy (4.21% [95% CI, 1.37% to 7.15%]), a statistically significant difference ( P = .046, a = 0.05). A similar rate of infectious dental emergencies was observed in the prescreening group (4.28% [95% CI, 2.0% to 7.2%]). CONCLUSION: Clinical dental screening before induction chemotherapy in patients with AML resulted in a 6-fold reduction in infectious dental emergencies during the induction period.
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Oncology (nursing),Health Policy,Oncology
Reference20 articles.
1. Prognostic factors in acute myelogenous leukemia
2. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia
3. Therapeutic options for acute myelogenous leukemia
4. Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience.
5. Kebriaei P, Champlin R, de Lima M, et al: Management of acute leukemias, in DeVita VT, Lawrence TS, Rosenberg SA (eds): DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology (ed 9). Philadelphia, PA, Wolters Kluwer Health/Lippincott Williams & Wilkins, 2014, pp 1928-1954
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献